Pharmaceutical industry financial penalties in U.S. by violation type 1991-2017

This statistic represents the amount of money the pharmaceutical industry in the U.S. had to pay in financial penalties from 1991 to 2017, by type of violation. Over this time the pharmaceutical industry paid some 1.8 billion U.S. dollars in financial penalties due to poor manufacturing practices in which they sold drug products that failed to meet FDA standards or specifications.

Pharmaceutical industry financial penalties in the U.S. from 1991 to 2017, by type of violation (in million U.S. dollars)

Characteristic	In million U.S. dollars
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

March 2018

More information

Region

United States

Survey time period

1991 to 2017

Supplementary notes

* Since the publication of the 2016 report, an additional federal, non-qui-tam settlement with Syncor, in 2002 for $2.5 million ($0.5 million civil penalty; $2 million criminal penalty) for kickbacks, was found and added to the database.
** Settlements that involved more than one type of violation were reviewed and, where possible, individual penalties for each type of violation were determined and added to the totals for that violation. The final total for “multiple violations” represents the sum total that could not be (or was not) attributed to a single violation.

Citation formats